Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Q2FY23 Quarterly Result Announced for Alembic Pharmaceuticals Ltd.

 Alembic Pharmaceuticals announced Q2FY23 results: Q2FY23 & H1FY23: Net Sales for the quarter were up 14% to Rs 1,475 crore. Net Profit for the quarter at Rs 133 crore. Net sales for H1FY23 at Rs 2,737 crore. Net profit for H1FY23 at Rs 67 crore. Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said "It was a satisfactory quarter led by growth in all the verticals of the company, in particular the API business outperformed with a 23% growth during the quarter" Result PDF
11-11-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2022

 With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved the Unaudited Financial Results for the quarter and half year ended 30th September, 2022.
11-11-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Board Meeting Outcome for Outcome Of Board Meeting

 With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved the Unaudited Financial Results for the quarter and half year ended 30th September, 2022.
11-11-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimation dated 10th November, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request(s)/application(s) from the registered shareholder(s) of the Company for issue of Duplicate Share Certificate(s).
10-11-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 The exchange is hereby informed that the Company's Post Results Conference Call will be held on 11th November, 2022 at 5:30 p.m., as per the revised details enclosed.
09-11-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 With reference to the captioned subject, please find enclosed herewith the intimation dated 7th November, 2022 received from Link lntime India Private Limited, Registrar and Share Transfer Agent, regarding receipt of the request(s)/application(s) from the registered shareholder(s) of the Company for issue of Duplicate Share Certificate(s).
07-11-2022

Alembic Pharma jumps 8% as it gets final FDA approval on injectable drug

 Ketorolac Tromethamine Injection USP has an estimated market size of $59 million for twelve months ending June 2022 according to IQVIA.
03-11-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Alembic Pharmaceuticals announces its second injectable product approval from its General Sterile Facility - Final Approval for Ketorolac Tromethamine Injection USP.
03-11-2022

Alembic Pharma receives final approval from USFDA for generic Mesalamine extended-release capsules

 The approval granted by the US Food Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Mesalamine Extended-Release Capsules of strength 0.375 g, the company said in a statement.
02-11-2022
Bigul

ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Mesalamine Extended-Release Capsules USP, 0.375 g.
02-11-2022
Next Page
Close

Let's Open Free Demat Account